Apellis is a global biopharmaceutical company that combines courageous science, creativity, and compassion to deliver life-changing medicines. We are exploring the potential of targeting C3, the central protein of the complement system. With four Phase 3 studies in two disease areas underway, Apellis has emerged as the leader in the research of targeted C3 therapies.
We are developing intravitreal pegcetacoplan (APL-2), an investigational targeted C3 therapy that has the potential to be the first approved treatment for geographic atrophy (GA). In July 2020, we announced that Apellis completed enrollment in the Phase 3 DERBY and OAKS studies investigating intravitreal pegcetacoplan in GA secondary to age-related macular degeneration (AMD). We anticipate top-line results from these two pivotal studies, enrolling a total of 1,259 patients, in Q3 2021.